A. Frilling et al., Use of somatostatin receptor scintigraphy to image extrahepatic metastasesof neuroendocrine tumors, SURGERY, 124(6), 1998, pp. 1000-1004
Background. The presence of lymph node metastases significantly influences
the modality of treatment in patients with liver metastases of neuroendocri
ne tumors (NET). Somatostatin receptor scintigraphy (Octreo-Scan, Mallinckr
odt-Diagnostica, Petten, the Netherlands) is a method for localization and
staging NET: The aim of our prospective study was to evaluate the effective
ness of somatostatin receptor scintigraphy in the identification of extrahe
patic tumor spread.
Methods. Thirty-five patients with liver metastases of NET were studied ove
r a 5-year period. The presence of NET was confirmed histologically in all
cases. To detect extrahepatic metastases or local tumor recurrence, convent
ional imaging techniques and somatostatin receptor scintigraphy were carrie
d out.
Results. In correlation with the findings of conventional imaging methods,
somatostatin receptor scintigraphy confirmed liver metastases in all patien
ts. Additionally, 19 of 35 patients (54.2 %) had extrahepatic: tumor lesion
s not detected by other imaging techniques. Of those, 15 had extensive abdo
minal or thoracic lymph node metastases, 3 patients had bone metastases, an
d in 1 patient with bronchial carcinoid local tumor recurrence was detected
. All 19 patients were excluded from further evaluation for liver resection
or transplantation and subjected to conservative treatment. The somatostat
in receptor scintigraphy sensitivity, confirmed at the time of operation, w
as 91.6%. In I patient, in whom cluster transplantation was performed, soma
tostatin receptor scintigraphy failed to disclose disseminated carcinosis o
f the pleural cavity, detected at autopsy (false-negative rate 8.3 %).
Conclusion. In our experience, somatostatin receptor scintigraphy provides
a highly sensitive diagnostic method to localize metastases of NET: We reco
mmend somatostatin receptor scintigraphy before liver surgery in every pati
ent with hepatic metastases of NET to identify candidates suitable for rese
ction.